STAT Plus: The J&J opioid case in Oklahoma darkens the outlook for other drug companies
Now that an Oklahoma state court judge has ruled Johnson & Johnson (JNJ) must pay $572 million to the state for contributing to the opioid crisis there, Wall Street is engaged in a parlor game seeking to answer a key question: How will this decision affect the massive amount of litigation elsewhere?
Sorting this out takes us in a number of directions because there are lawsuits filed against different drug makers in different states, along with a huge case consolidated in a federal court in Cleveland. There are also varying legal issues in play, increasing pressure to reach settlements, and uncertainty about the extent to which drug companies have the ability to reach any number of deals.
Continue to STAT Plus to read the full story…
